Wai Ling Wong

US Patent:

6869772, Mar 22, 2005

Filed:

Mar 9, 2001

Appl. No.:

09/802644

Inventors:

Jeff W. Lichtman - St. Louis MO, US
Wai T. Wong - Philadelphia PA, US
Rachel Wong - University City MO, US
Jamie Grutzendler - St. Louis MO, US

Assignee:

Washington University - Saint Louis MO

International Classification:

G01N001/30
C12N015/87

US Classification:

435 405, 435459, 427 213

Abstract:

A method is provided for the labeling of individual cells. Labeling is accomplished by coating a particle with at least one dye or nucleic acid sequence encoding a marker protein. The particle is then propelled toward the cell resulting in the particle contacting the cell for a time sufficient for the dye or nucleic acid to leave the particle and enter the cell. The present method allows for the differential labeling of individual cells within dense populations of cells.

US Patent:

60573503, May 2, 2000

Filed:

Jun 17, 1998

Appl. No.:

9/098781

Inventors:

Michael A. Patane - Harleysville PA
Mark G. Bock - Hatfield PA
Dhanapalan Nagarathnam - Ramsey NJ
Bharat Lagu - Maywood NJ
Wai C. Wong - Newark NJ

Assignee:

Merck & Co., Inc. - Rahway NJ
Synaptic Pharmaceutical Corp. - Paramus NJ

International Classification:

A61K 3142
A61K 31425
C07D26322
C07D27506

US Classification:

514376

Abstract:

This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.